Clinical review report: Satralizumab (Enspryng) (Hoffmann-La Roche Limited) : indication neuromyelitis optica spectrum disorder
The objective of this report is to perform a systematic review of the beneficial and harmful effects of satralizumab as monotherapy or in combination with immunosuppressive therapy for the treatment of NMOSD in adult and adolescent patients who are AQP4 antibody positive
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, June 2021
|
| Edition: | Version: Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report is to perform a systematic review of the beneficial and harmful effects of satralizumab as monotherapy or in combination with immunosuppressive therapy for the treatment of NMOSD in adult and adolescent patients who are AQP4 antibody positive |
|---|---|
| Physical Description: | 1 PDF file (92 pages) illustrations |